Abstract
During our investigation in pyrrole antibacterial area we have identified a subclass with a good potent in vitro activity against mycobacteria and fungi. We have individuated the salient structural feature and BM 212 as lead for the class. SAR studies allowed us to synthesize several analogue derivatives. Some of them revealed more active than BM 212 against mycobacteria, but they lost antifungal activity. In particular the Protection Index (PI) was very interesting for some derivatives, comparable to that of reference compounds, Isoniazid (INH), Streptomycin (SM) and Rifampin (RF). Many of the synthesized compounds revealed active against intracellular mycobacteria and they showed to be inhibitory to drug-resistant mycobacteria of clinical origin. On the base of microbiological results we have hypothesized a pharmacophore model that was also optimized. The rational design, and the evaluation of the in vitro activity against mycobacteria are described.
Current Medicinal Chemistry
Title: BM 212 and its Derivatives as a New Class of Antimycobacterial Active Agents
Volume: 9 Issue: 21
Author(s): Mariangela Biava
Affiliation:
Abstract: During our investigation in pyrrole antibacterial area we have identified a subclass with a good potent in vitro activity against mycobacteria and fungi. We have individuated the salient structural feature and BM 212 as lead for the class. SAR studies allowed us to synthesize several analogue derivatives. Some of them revealed more active than BM 212 against mycobacteria, but they lost antifungal activity. In particular the Protection Index (PI) was very interesting for some derivatives, comparable to that of reference compounds, Isoniazid (INH), Streptomycin (SM) and Rifampin (RF). Many of the synthesized compounds revealed active against intracellular mycobacteria and they showed to be inhibitory to drug-resistant mycobacteria of clinical origin. On the base of microbiological results we have hypothesized a pharmacophore model that was also optimized. The rational design, and the evaluation of the in vitro activity against mycobacteria are described.
Export Options
About this article
Cite this article as:
Biava Mariangela, BM 212 and its Derivatives as a New Class of Antimycobacterial Active Agents, Current Medicinal Chemistry 2002; 9 (21) . https://dx.doi.org/10.2174/0929867023368953
DOI https://dx.doi.org/10.2174/0929867023368953 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Advances and Application of DNA-functionalized Nanoparticles
Current Medicinal Chemistry Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer
Current Medicinal Chemistry Alcoholic Liver Disease and Hepatitis C Chronic Infection
Reviews on Recent Clinical Trials Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Analysis of Safety Outcomes in Chronic Hepatitis C Patients using Interferon-free Treatment: A Systematic Review of Case Reports
Current Drug Therapy New Insights about the Potential Application of the Association of Vitamins C (Sodium Ascorbate) and K3 (Menadione) as Auxiliary Therapy in Cancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Current Trends in the Chemotherapy of Colorectal Cancer
Current Medicinal Chemistry EBV-Associated Tumors: Pathogenetic Insights for Improved Disease Monitoring and Treatment
Current Cancer Therapy Reviews Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design 3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors
Letters in Drug Design & Discovery Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets